Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin for SARS-CoV-2 Susceptibility in AERD
NCT05797597Phase 3Unknown
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Aspirin First Sequence with Placebo First Sequence (2 arms). Primary endpoint: Number of Participants with two-fold decrease in gene expression of ACE2, TMPRSS2, BSG, PPIA, PPIB, DPP4, IFNA1, IFNB1, IFNG, IFNL1, IFNL2 and ISG at 8 weeks. Status: unknown.
02
Drugs
aspirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05797597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05797597.